ILiAD Biotechnologies Receives NIH Grant to Develop Novel Tuberculosis Vaccine using proprietary B-Tech Vector Platform : vimarsana.com

ILiAD Biotechnologies Receives NIH Grant to Develop Novel Tuberculosis Vaccine using proprietary B-Tech Vector Platform

ILiAD Biotechnologies Receives NIH Grant to Develop Novel Tuberculosis Vaccine using proprietary B-Tech Vector Platform

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Saclay , France General , France , Fontenay Aux Roses , Paris , Belgium , French , Peter Goldstein , Camille Locht , Ken Solovay , Jacob Institute Of Biology , French National Institute Of Health , Iliad Biotechnologies , National Institutes Of Health , National Institute Of Allergy , French Ministry Of National Education , Research Inserm , Ministry Of Social Affairs , Iliad Vector Technology , Vaccine Platform Development , National Institute , Infectious Diseases , National Institutes , Tech Vector Technology , Tuberculosis Vaccine Discovery , Tech Vector Platform , B Tech Technology , Institut Pasteur De Lille , Executive Director , B Tech Vector , B Tech Vector Platform , Biolyo Technologies , Lyo Technologies , French National Institute , Medical Research , French Ministry , National Education , Higher Education , Social Affairs , Jacob Institute , Saint Louis , Private Securities Litigation Reform Act ,